Plus Therapeutics Inc 2026年季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to PLUS THERAPEUTICS, INC. Table of Contents FINANCIAL INFORMATION Item 1.Consolidated Financial Statements (Unaudited) 4Condensed Consolidated Balance Sheets4Condensed Consolidated Statements of Operations5Condensed Consolidated Statements of Stockholders’ Equity/(Deficit)6Condensed Consolidated Statements of Cash Flows7Notes to Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations23Item 3.Quantitative and Qualitative Disclosures about Market Risk33Item 4.Controls and Procedures33 PART II.OTHER INFORMATION Item 1.Legal Proceedings33Item 1A.Risk Factors34Item 2.Unregistered Sales of Equity Securities and Use of Proceeds34Item 6.Exhibits35 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) and the exhibits incorporated herein by reference contain“forward-looking statements” which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933,as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements other than statements of historicalfactconstitute“forward-looking statements.”These forward-looking statements do not constitute guarantees of futureperformance. These forward-looking statements may be identified by terms such as “intend,” “expect,” “project,” “believe,” These statements include, without limitation, statements about our anticipated expenditures, including research and development,and general and administrative expenses; our intent or ability to maintain compliance with Nasdaq listing standards; our strategiccollaborations and license agreements, intellectual property, U.S. Food and Drug Administration and European Medicines Agencyapprovals and interactions and government regulation; our research and development efforts; the results from our preclinical andclinical studies and the implications of such results regarding the efficacy or safety of our product candidates; the safety profile,pathways, and efficacy of our product candidates and formulations; anticipated advantages of our product candidates over other Our actual results may differ, including materially, from those anticipated in these forward-looking statements as a result ofvarious factors, including, but not limited to, the following: our ability to remain listed on Nasdaq; the early stage of our productcandidates and therapies, the results of our research and development activities, including uncertainties relating to the clinicaltrials of our product candidates and therapies; sources of competition for any of our product candidates; the potential size of themarket for our product candidates; our pipeline; our ability to generate product or development revenue and the sources of suchrevenue; our ability to effectively manage our gross profit margins; our ability to obtain and maintain regulatory approvals;expectations as to our future performance; our ability to satisfy our obligations under the terms of our capital raising transactionsincluding registering shares issuable in such transactions; our ability to integrate into our business and operations, develop, fullyutilize and monetize acquired assets; our ability to continue as a going concern; our ability to repay or refinance some or all of ouroutstanding indebtedness and our ability to raise capital in the future; our ability to transfer the drug and medical device productmanufacturing to a contract drug and medical device manufacturing organization; the potential enhancement of our cash positionthroughdevelopment,marketing,and licensing arrangements;our ability to timely and efficiently launch our CNSide® We caution you not to place undue reliance on the forward-looking statements contained in this Quarterly Report. Thesestatements, like all statements in this report, speak only as of the date of this report (unless an earlier date is indicated) and theCompany undertakes no obligation to update or revise the statements except as required by law. Such forward-looking statements Table of Contents PLUS THERAPEUTICS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS PLUS THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS PLUS THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS PLUS THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1.Organization and Basis of Presentation Description of Business Plus Therapeutics, Inc. (the “Company”) is a U.S. healthcare company developing and commercializing precision diagnosticsand targeted radiopharmaceuticals for central nervous system (“CNS”) cancers. CNSide Diagnostics, LLC (“CNSideDiagnostics”